Screener
Xeris Biopharma Holdings, Inc. XERS Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|
| Net cash provided by (used in) operating activities | 18,133 | (9,849) |
| Cash flows from investing activities: | ||
| Capital expenditures | (534) | (292) |
| Net cash used in investing activities | (534) | (292) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of employee stock purchase plan shares | 985 | 830 |
| Proceeds from exercise of stock options | 1,396 | 5,833 |
| Proceeds from issuance of common shares in settlement of warrants | 7,933 | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s investing cash flow?
- Xeris Biopharma Holdings, Inc. (XERS) reported investing cash flow of -$209K in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s investing cash flow changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s investing cash flow increased by 25.1% year-over-year, from -$279K to -$209K.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s investing cash flow?
- Over 2 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s investing cash flow has grown at a -91.6% compound annual growth rate (CAGR), from $97.96M to -$696K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Xeris Biopharma Holdings, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude